1 Recommendations
1.1 Ponatinib is recommended, within its marketing authorisation, as an option for treating chronic‑, accelerated‑ or blast‑phase chronic myeloid leukaemia in adults when:
-
the disease is resistant to dasatinib or nilotinib or
-
they cannot tolerate dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or
-
the T315I gene mutation is present.
1.2 Ponatinib is recommended, within its marketing authorisation, as an option for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults when:
-
the disease is resistant to dasatinib or
-
they cannot tolerate dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate or
-
the T315I gene mutation is present.
1.3 Ponatinib is recommended only if the company provides the drug with the discount agreed in the patient access scheme.